Development of a Microsphere‐based Immunoassay for Serological Detection of African Horse Sickness Virus and Comparison with Other Diagnostic Techniques. Issue 6 (19th February 2015)

• Record Type: Journal Article
• Authors: Sánchez‐Matamoros, A.; Beck, C.; Kukielka, D.; Lecollinet, S.; Blaise‐Boisseau, S.; Garnier, A.; Rueda, P.; Zientara, S.; Sánchez‐Vizcaíno, J. M.
• Is Part Of: Transboundary and emerging diseases. Volume 63:Issue 6(2016)
• Page Start: e270
• Page End: e277
• Publication Date: 2015-02-19
• Subjects: African horse sickness -- antibody detection -- bead‐based multiplex immunoassay -- diagnosis -- serology; Veterinary medicine -- Periodicals; 636.089
• DOI: 10.1111/tbed.12340
• Languages: English
• ISSNs: 1865-1674

Abstract

Summary: African horse sickness (AHS) is a viral disease that causes high morbidity and mortality rates in susceptible Equidae and therefore significant economic losses. More rapid, sensitive and specific assays are required by diagnostic laboratories to support effective surveillance programmes. A novel microsphere‐based immunoassay (Luminex assay) in which beads are coated with recombinant AHS virus (AHSV) structural protein 7 (VP7) has been developed for serological detection of antibodies against VP7 of any AHSV serotype. The performance of this assay was compared with that of a commercial enzyme‐linked immunosorbent assay (ELISA) and commercial lateral flow assay (LFA) on a large panel of serum samples from uninfected horses ( n = 92), from a reference library of all AHSV serotypes ( n = 9), on samples from horses experimentally infected with AHSV ( n = 114), and on samples from West African horses suspected of having AHS ( n = 85). The Luminex assay gave the same negative results as ELISA when used to test the samples from uninfected horses. Both assays detected antibodies to all nine AHSV serotypes. In contrast, the Luminex assay detected a higher rate of anti‐VP7 positivity in the West African field samples than did ELISA or LFA. The Luminex assay detected anti‐VP7 positivity in experimentally infected horses at 7 days post‐infection, compared to 13 days for ELISA. This novel immunoassay provides a platform for developing multiplex assays, in which the presence of antibodies against multiple ASHV antigens can be detected simultaneously. This would be useful for serotyping or for differentiating infected from vaccinated animals.